Corrigendum to “Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial” [Eur. Urol. 86(2) (2024) 90–94]

Abstract

The authors regret that four incorrect estimates pertaining to adverse event (AE) incidence were stated in the text, discrepant from the corresponding tables where correct estimates were included. Specifically, incorrect values were stated in the text for incidence of the following treat treatment-related AEs: 1) AEs of any grade, 2) grade 3-4 AEs, 3) grade 3-4 AST events, and 4) grade 3-4 ALT events. Correct values were included the corresponding supplemental tables 2 and 4, and are stated here: Treatment-related AEs of any grade were experienced by 40 patients (100%); grade 3-4 AEs were experienced by 20 patients (50%). Treatment-related grade 3-4 AST and ALT elevations were 13% and 15% respectively.